[go: up one dir, main page]

KR920703831A - 백신(vaccines) - Google Patents

백신(vaccines)

Info

Publication number
KR920703831A
KR920703831A KR1019920701760A KR920701760A KR920703831A KR 920703831 A KR920703831 A KR 920703831A KR 1019920701760 A KR1019920701760 A KR 1019920701760A KR 920701760 A KR920701760 A KR 920701760A KR 920703831 A KR920703831 A KR 920703831A
Authority
KR
South Korea
Prior art keywords
gene
adenovirus
promoter
dog
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920701760A
Other languages
English (en)
Inventor
노르만 스피베이
Original Assignee
원본 미기재
더 유니버시티 코트 오브 더 유니버시티 오브 글래스고
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본 미기재, 더 유니버시티 코트 오브 더 유니버시티 오브 글래스고 filed Critical 원본 미기재
Publication of KR920703831A publication Critical patent/KR920703831A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음

Description

백신(vaccines)
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 상기 항체 또는 면역원 비병원성 양의 세포 마개 면역 요소의 유전자 단백질 합성에 대해 형성되고 배열되는 상기 유전자에 대해 효과적인 프로모터에 관련하여, 상기 항체에 대응하고 또는 상기 세포 매개 면역을 일으키는 항원에 대한 유전자 코딩을 포함하기 위해 수정된 생 비병원성 면역원 생균 개의 아데노 바이러스로 구성되는 육식동물의 감염 생물체에 항체 또는 세포 매개 면역 생성을 위한 재조합 아데노바이러스.
  2. 제1항에 있어서. 상기 프로모터 유전자 배열을 포함하기 위해 수정된 CAV-2 균주가 있는 아데노바이러스.
  3. 선행 청구범위 중 어느 항에 있어서, 프로머터 유전자 배열이 전환말기의 반복(ITR)의 말단에 가까운 Sma I 위치부터 초기 지역 4(E4)에 대한 프로모터에 이르기 까지 뻗어있는 바이러스성 게놈의 지역으로 삽입되는 아데노 바이러스.
  4. 제3항에 있어서, 프로모터 유전자 배열이 Sma I 위치안에 삽입되는 아데노 바이러스.
  5. 선행 청구범위 중 어느 항에 있어서, 삽입된 유전자가 다음부터 선택된 면역원 유전자 분절이거나 유전자인 아데노바이러스 : (a) 개의 파르보바이러스의 캡시드 단백질에 대한 유전자, (b) 고양이 잡백혈구의 캡시드 단백질에 대한 유전자, (c) 개와 고양이 코르노바이러스의 페플로메르(peplomeres)에 대한 유전자, (d) 개의 디스템퍼 바이러스의 혈구응집반응과 캡시드 항윈에 대한 유전자, (e) 고양이의 백혈병 바이러스의 외피 당단백질에 대한 유전자, (f) 광견명 바이러스의 외피 당단백질에 대한 유전자 및 (g) 고양이의 면역부전 바이러스의 외피 당단백질에 대한 유전자.
  6. 선행 청구범위 중 어느 항에 있어서, 개의 아데노바이러스 Ela 단백질과 결합하는 재조합 아데노바이러스.
  7. 면역원 비병원성 양의 세포 매개 면역 요소 또는 상기 항체의 유전자 단백질 합성에 대해 형성되고 배열된 상기 유전자에 대한 효과적인 프로모터와 관련하여 상기 항체에 대응하고 또는 상기 세포 매개 면역을 일으키는 항원에 대한 유전자 코딩을 포함하기 위하여 생 비병윈성 면역원 생균 개의 아데노바이러스를 수정하는 것으로 구성되는 육식동물의 감염 생물체에 세포 매개 면역 또는 항체 생성용 제조합 아데노바이러스 조제방법.
  8. 제7항에 있어서, 재조합 바이러스가 개의 아데노바이러스 Ela 단백질을 명시하는 세포 라인 안에서 트랜스펙션에 의해 복제되는 방법.
  9. 제1항 내지 제6항 중 어느 항에 있어서, 상기 생 비병원성 면역원 생균 개의 아데노바이러스 및 프로모터 인자 유전자 배열로 부터 DNA 배열 분절을 포함하는 플라스미드.
  10. 제1항 내지 제6항 중 어느 항에 있어서, 수용가능한 매개체와 서로 재조합 아데노바이러스로 구성되는 백신형태.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920701760A 1990-01-25 1991-01-25 백신(vaccines) Withdrawn KR920703831A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909001766A GB9001766D0 (en) 1990-01-25 1990-01-25 Vaccines
GB9001766.6 1990-01-25
PCT/GB1991/000107 WO1991011525A2 (en) 1990-01-25 1991-01-25 Vaccines

Publications (1)

Publication Number Publication Date
KR920703831A true KR920703831A (ko) 1992-12-18

Family

ID=10669925

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701760A Withdrawn KR920703831A (ko) 1990-01-25 1991-01-25 백신(vaccines)

Country Status (14)

Country Link
EP (1) EP0512017B1 (ko)
JP (1) JP3159446B2 (ko)
KR (1) KR920703831A (ko)
AU (1) AU641211B2 (ko)
CA (1) CA2074502C (ko)
DE (1) DE69126606T2 (ko)
DK (1) DK0512017T3 (ko)
ES (1) ES2103001T3 (ko)
GB (1) GB9001766D0 (ko)
GR (1) GR3024242T3 (ko)
HU (1) HUT65368A (ko)
NZ (1) NZ236887A (ko)
WO (1) WO1991011525A2 (ko)
ZA (1) ZA91534B (ko)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213743T3 (es) * 1991-04-25 2004-09-01 Akzo Nobel N.V. Vacuna de subunidad de coronavirus canino.
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US6099831A (en) * 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
DE69740033D1 (de) * 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
AU8097698A (en) 1997-06-23 1999-01-04 University Of Saskatchewan Bovine adenovirus type 3 genome
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
CA2410665C (en) 2000-05-31 2017-11-07 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US6916635B2 (en) 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
FR2845395B1 (fr) * 2002-10-08 2008-05-30 Agronomique Inst Nat Rech Vecteurs adenoviraux recombinants et leurs applications
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
US20050202484A1 (en) 2004-02-19 2005-09-15 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
CA2605629C (en) 2005-04-25 2012-06-26 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
WO2007056614A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
DK2414386T3 (en) 2009-04-03 2016-02-22 Merial Ltd Birds of vaccines with newcastle disease virus vectors
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
EP2701736A1 (en) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
LT2741740T (lt) 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN107922462B (zh) 2015-06-23 2022-03-18 勃林格殷格翰动物保健美国公司 含prrsv次要蛋白的重组病毒载体及其制造方法与用途
TWI799365B (zh) 2015-08-31 2023-04-21 德商百靈佳殷格翰維美迪加股份有限公司 用於先天性痙攣症之瘟疫病毒疫苗
US20170072042A1 (en) 2015-09-16 2017-03-16 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
KR102566066B1 (ko) 2016-09-20 2023-08-16 베링거잉겔하임베트메디카게엠베하 신규한 돼지 인플루엔자 백신
KR102543774B1 (ko) 2016-09-20 2023-06-19 베링거잉겔하임베트메디카게엠베하 신규한 프로모터
JP6952112B2 (ja) 2016-09-20 2021-10-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 新規なｅｈｖ挿入部位ｏｒｆ７０
AU2017353380B2 (en) 2016-11-03 2024-08-22 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
JP6876127B2 (ja) 2016-11-03 2021-05-26 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ ブタパルボウイルスに対するワクチン
US12150983B2 (en) 2017-01-30 2024-11-26 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
WO2019014144A1 (en) 2017-07-12 2019-01-17 Boehringer Ingelheim Vetmedica, Inc. IMMUNOGENIC COMPOSITIONS BASED ON SENECAVIRUS TYPE A AND CORRESPONDING METHODS
BR112020005767A2 (pt) 2017-09-23 2020-10-13 Boehringer Ingelheim Vetmedica Gmbh sistema de expressão de paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
MX2020008779A (es) 2018-02-23 2020-10-01 Boehringer Ingelheim Vetmedica Gmbh Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exogenos y vacunas elaboradas a partir de estos.
CA3091960A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site ul43
JP7273840B2 (ja) 2018-03-19 2023-05-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 不活性化ｕｌ１８および／またはｕｌ８を有する新しいｅｈｖ
TW202003027A (zh) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 製造免疫原組合物之方法
WO2020058341A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Intranasal vector vaccine against porcine epidemic diarrhea
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
EP4100420A1 (en) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
EP4225361A1 (en) 2020-10-05 2023-08-16 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
CA3195910A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies

Also Published As

Publication number Publication date
AU7075691A (en) 1991-08-21
CA2074502C (en) 2001-07-17
EP0512017A1 (en) 1992-11-11
GB9001766D0 (en) 1990-03-28
DE69126606T2 (de) 1998-01-08
HUT65368A (en) 1994-05-02
GR3024242T3 (en) 1997-10-31
JPH05505306A (ja) 1993-08-12
JP3159446B2 (ja) 2001-04-23
ES2103001T3 (es) 1997-08-16
CA2074502A1 (en) 1991-07-26
WO1991011525A3 (en) 1991-09-05
DE69126606D1 (de) 1997-07-24
AU641211B2 (en) 1993-09-16
ZA91534B (en) 1991-11-27
HU9202436D0 (en) 1992-12-28
WO1991011525A2 (en) 1991-08-08
EP0512017B1 (en) 1997-06-18
NZ236887A (en) 1992-04-28
DK0512017T3 (da) 1998-01-19

Similar Documents

Publication Publication Date Title
KR920703831A (ko) 백신(vaccines)
DE3751092T2 (de) Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.
KR970008217B1 (ko) 재조합 백신
Pitcovski et al. Insect cell-derived VP2 of infectious bursal disease virus confers protection against the disease in chickens
Fodor et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens
DE69223939D1 (de) Verfahren zur herstellung von untereinheitsimpfstoff gegen hundeparvovirus und verwandten viren
KR880700070A (ko) 비루스 왁찐
AU571128B2 (en) Expression of immunologically reactive aids viral protein
EP0341611A2 (en) Subunit canine parvovirus vaccine and method of making the same
JP2006238887A (ja) 組換えブタポックスウイルス
CA2110505A1 (en) Infectious bursal disease virus recombinant poxvirus vaccine
DE68912478D1 (de) Rekombinantes Marek-Krankheitsvirus, Verfahren zu seiner Herstellung, und Vakzine.
Romito et al. Eliciting antigen-specific egg-yolk IgY with naked DNA
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
Agterberg et al. Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE-FMDV hybrid protein
AU686000B2 (en) Infectious peritonitis vaccine
Xiao et al. VP2 virus‐like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks
Ono et al. Expression of Marek's disease virus (MDV) serotype 2 gene which has partial homology with MDV serotype 1 pp38 gene
Nagy et al. Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter
Bouges-Bocquet et al. In vitro genetic constructions devised to express given antigenic determinants at the surface of gram-negative bacteria.
WO2005007827A2 (en) Avian adeno-associated virus vector
KR920007636A (ko) 신규의 백신체
CN1616107A (zh) 一种子宫颈癌基因工程重组疫苗
Yong-Ke et al. Construction and characterization of a recombinant Fowlpox virus expressing chicken type II interferon
Tikhonenko Prospects and achievements in the development of genetically engineered antiviral vaccines.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920725

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid